JP2009534367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009534367A5 JP2009534367A5 JP2009505965A JP2009505965A JP2009534367A5 JP 2009534367 A5 JP2009534367 A5 JP 2009534367A5 JP 2009505965 A JP2009505965 A JP 2009505965A JP 2009505965 A JP2009505965 A JP 2009505965A JP 2009534367 A5 JP2009534367 A5 JP 2009534367A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- treatment
- composition according
- agonist
- functional muscarinic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 239000000556 agonist Substances 0.000 claims 11
- 230000003551 muscarinic effect Effects 0.000 claims 11
- 206010001497 Agitation Diseases 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 7
- 206010012374 Depressed mood Diseases 0.000 claims 5
- 238000013019 agitation Methods 0.000 claims 5
- 208000019116 sleep disease Diseases 0.000 claims 5
- 206010011971 Decreased interest Diseases 0.000 claims 4
- 206010041243 Social avoidant behaviour Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- 206010027175 memory impairment Diseases 0.000 claims 3
- 208000037048 Prodromal Symptoms Diseases 0.000 claims 2
- 230000001713 cholinergic effect Effects 0.000 claims 2
- 230000006866 deterioration Effects 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 230000002536 noncholinergic effect Effects 0.000 claims 2
- 208000022925 sleep disturbance Diseases 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0607952.9A GB0607952D0 (en) | 2006-04-21 | 2006-04-21 | Novel treatment |
| PCT/GB2007/001463 WO2007125287A1 (en) | 2006-04-21 | 2007-04-23 | Mono and combination therapy with m1/m4 muscarinic agonist (sabcomeline) for treatment of prodromal syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009534367A JP2009534367A (ja) | 2009-09-24 |
| JP2009534367A5 true JP2009534367A5 (enExample) | 2010-06-17 |
Family
ID=36581049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009505965A Pending JP2009534367A (ja) | 2006-04-21 | 2007-04-23 | 前駆症状症候群の治療にｍ１／ｍ４ムスカリン性アゴニスト（サブコメリン）を用いる単独及び組合せ療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20090318414A1 (enExample) |
| EP (1) | EP2012783A1 (enExample) |
| JP (1) | JP2009534367A (enExample) |
| CN (1) | CN101472586A (enExample) |
| CA (1) | CA2649590A1 (enExample) |
| GB (1) | GB0607952D0 (enExample) |
| WO (1) | WO2007125287A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3061821B1 (en) | 2009-07-22 | 2019-07-10 | Puretech Health LLC | Compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| MX373274B (es) | 2014-04-23 | 2020-04-16 | Takeda Pharmaceuticals Co | Derivados de isoindolin-1-ona con actividad de modulador alostérico positivo del receptor colinérgico muscarínico m1 para el tratamiento de la enfermedad de alzheimer. |
| KR20180019234A (ko) | 2015-06-26 | 2018-02-23 | 다케다 야쿠힌 고교 가부시키가이샤 | 콜린성 무스카린 m1 수용체의 조절제로서의 2,3-디히드로-4h-1,3-벤족사진-4-온 유도체 |
| WO2017069173A1 (ja) | 2015-10-20 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
| US10933020B2 (en) | 2018-09-28 | 2021-03-02 | Karuna Therapeutics, Inc. | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE269330T1 (de) * | 1989-04-13 | 2004-07-15 | Beecham Group Plc | Chemische verbindungen |
| GB0008921D0 (en) * | 2000-04-11 | 2000-05-31 | Smithkline Beecham Plc | Method of treatment |
| US20010036949A1 (en) * | 2000-05-09 | 2001-11-01 | Coe Jotham Wadsworth | Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
| DE60116313T2 (de) * | 2000-06-30 | 2006-08-31 | Elan Pharmaceuticals, Inc., San Francisco | Verbindungen zur behandlung der alzheimerischen krankheit |
| US20040023951A1 (en) * | 2001-06-18 | 2004-02-05 | Bymaster Franklin Porter | Combination therapy for treatment of psychoses |
| NZ533566A (en) * | 2001-12-28 | 2007-03-30 | Acadia Pharm Inc | Tetrahydroquinoline analogues as muscarinic agonists |
| GB0428180D0 (en) * | 2004-12-23 | 2005-01-26 | Biopartners Ltd | Combination therapy |
-
2006
- 2006-04-21 GB GBGB0607952.9A patent/GB0607952D0/en not_active Ceased
-
2007
- 2007-04-23 US US12/226,423 patent/US20090318414A1/en not_active Abandoned
- 2007-04-23 WO PCT/GB2007/001463 patent/WO2007125287A1/en not_active Ceased
- 2007-04-23 CA CA002649590A patent/CA2649590A1/en not_active Abandoned
- 2007-04-23 CN CNA2007800232331A patent/CN101472586A/zh active Pending
- 2007-04-23 JP JP2009505965A patent/JP2009534367A/ja active Pending
- 2007-04-23 EP EP07732503A patent/EP2012783A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lara et al. | Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression | |
| Malhotra et al. | Nicotine and periodontal tissues | |
| JP2022180461A5 (enExample) | ||
| JP2010525050A5 (enExample) | ||
| JP2008044951A5 (enExample) | ||
| JP2009530385A5 (ja) | うつ病の治療のためのケタミンの投与 | |
| JP2009525343A5 (enExample) | ||
| WO2018136554A1 (en) | Use of neurokinin-1 antagonists as antitussives | |
| RU2019100425A (ru) | Новая доза и препаративная форма | |
| JP2014528474A5 (enExample) | ||
| CN101772346A (zh) | 用于降低治疗副作用的方法和组合物 | |
| ME02662B (me) | Niskofrekventna terapija glatiramer acetatom | |
| AR065579A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| WO2007012019A3 (en) | Medicaments containing famotidine and ibuprofen and administration of same | |
| JP2009534367A5 (enExample) | ||
| NZ606383A (en) | Methods of treating pulmonary disorders with liposomal amikacin formulations | |
| JP2012505222A (ja) | 肺炎症を低減するためのレボフロキサシンの吸入 | |
| JP2010522137A5 (enExample) | ||
| SI2501234T1 (en) | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2013541583A5 (enExample) | ||
| JP2013516493A5 (enExample) | ||
| JP2005508963A5 (enExample) | ||
| JP2019514990A5 (enExample) |